Tempus AI Rises on Acquisition and Analyst Hike But Insider Sales and Weak Volume Sink Market Enthusiasm 269th in Activity

On August 28, 2025, Tempus AI (TEM) closed with a 0.59% gain, trading at $76.30. The stock saw a trading volume of $0.39 billion, a 21.53% decline from the prior day, ranking 269th in market activity. Key developments included a $81 million acquisition of AI pathology company Paige to bolster its AI model development, alongside a price target increase to $85 from $75 by BTIG analysts. Institutional investors such as Hsbc and Jump Financial also added to their stakes, signaling confidence in the company’s strategic direction.

However, insider selling activity weighed on sentiment, with multiple executives, including the CEO and CFO, offloading shares totaling over $1.3 million. This followed a broader trend of mixed options market sentiment and reduced call volume, indicating cautious positioning among traders. Despite the acquisition-driven optimism, the stock’s trading volume contraction highlighted limited immediate market enthusiasm for the transaction or analyst upgrades.

Backtest results for the period showed a query limit exceeded error, underscoring potential constraints in data accessibility for evaluating historical performance. The stock’s mixed technical and fundamental signals reflect ongoing uncertainty around its valuation and growth trajectory in the AI healthcare sector.